Skip to main content
. 2020 Jul 15;16(7):1091–1098. doi: 10.5664/jcsm.8432

Table 2.

Clinical characteristics of stage III and IV lung cancer.

Total (n = 16) AHI < 30 events/h AHI ≥ 30 events/h P
(n = 5) (n = 11)
Age, y 62.4 ± 11.5 64.2 ± 10.9 63.3 ± 11.4 > .99
Sex, male 15 4 11 .31
BMI 26.8 ± 4.2 25.8 ± 4.3 27.2 ± 4.3 .46
Smoker, PKY 43.1 ± 40.5 20.0 ± 15.8 53.6 ± 44.3 .09
ECOG status 1 ±.6 .8 ± .4 1.1 ± .7 .43
Polysomnography
 AHI 43.3 ± 29.4 10.8 ± 8.9 59.5 ± 20.8 < .01*
 ODI 28.2 ± 25.8 7.8 ± 4.0 41.0 ± 25.5 < .01*
 Lowest SpO2 81.8 ± 6.9 84.0 ± 5.3 80.7 ± 7.5 .50
Tsat90% 19.1 ± 27.1 2.5 ± 2.1 29.5 ± 31.5 .05
Tsat90 mins 29.8 ± 56.6 5.2 ± 5.0 41.0 ± 66.0 .16
PFS, months 18.4 ± 29.2 42.4 ± 45.2 7.5 ± 6.3 .03*
3-y mortalitya (%) 81.3 40 100 .08
5-y mortalitya (%) 93.7 80 100 .31
Cancer stage (%) .55
 Stage III 4 (25) 2 (40) 2 (18)
 Stage IV 12 (75) 3 (60) 9 (82)
Pathology (%) .59
 Adenocarcinoma 10 (66) 4 (80) 6 (55)
 Squamous cell 3 (18) 1 (20) 2 (18)
 Other 3 (18) 0 (0) 3 (27)
EGFR mutation 7 3 4 > .99
No mutation 3 1 2
First-line cancer treatment .36
 Target therapy 4 3 4
 CCRT 3 2 1
 Chemotherapy 4 0 4
 Radiotherapy 1 0 1
 Supportive care 1 0 1
Comorbid disease
 COPD 1 0 1 > .99
 Ischemic heart disease 4 1 3 > .99
 Diabetes mellitus 5 1 4 > .99
 Hypertension 8 2 6 > .99

Data presented as mean ± SD or number (percentage). *Cancer-related mortality. BMI = body mass index, CCRT = concurrent chemoradiotherapy, COPD = chronic obstructive pulmonary disease, ECOG = Eastern Cooperative Oncology Group, EGFR = epidermal growth factor receptor, ODI = oxygen desaturation index, PFS = progression-free survival, PKY = packs per year, SpO2 = oxygen saturation, Tsat90% = percentage of sleep time with oxygen saturation < 90%, Tsat90 mins = total sleep time (minutes) with oxygen saturation < 90%.